Testing stool and urine samples to find infections in people with weak immune systems
Tests whether genetic testing of stool and urine finds more germs in immunocompromised patients.
Plain-language title generated from the registry record
Registry title: Performance of Clinical Metagenomics in Stool and Urine Samples for Unexplained Diseases Diagnostic and Emerging Diseases Surveillance in Immunocompromised Patients
Key facts
- Where
- Paris, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults with a weak immune system who may have an infection and are having a metagenomic test (mNGS) on tissue, CSF, BAL or blood.
- Age
- Children and adults; no exact age range is given.
- Sex
- Men and women can join.
- Disease stage
- A primary or secondary immune deficiency, including immunosuppressive therapy, chemotherapy or HIV infection, with signs of infection such as fever, high white cell count or high CRP.
Main reasons for not taking part
- No healthcare insurance
Read by machine on 12 November 2026.
Where in France
- Hopital Necker Enfants MaladesParis, FranceContact: Jacques FOURGEAUD, PharmD, PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07603453
- Record updated
- 22 May 2026
- Original description
The study is based on the hypothesis that the concomitant use of mNGS in non-invasive samples (stool, urine) could improve the rate of detected pathogens in immunodeficient patients compared with mNGS performed in an invasive reference sample alone (blood, CSF, broncho-alveolar lavage fluid (BAL), tissue).Read full original descriptionShow less
Performance of Clinical Metagenomics in Stool and Urine Samples for Unexplained Diseases Diagnostic and Emerging Diseases Surveillance in Immunocompromised Patients
The study is based on the hypothesis that the concomitant use of mNGS in non-invasive samples (stool, urine) could improve the rate of detected pathogens in immunodeficient patients compared with mNGS performed in an invasive reference sample alone (blood, CSF, broncho-alveolar lavage fluid (BAL), tissue).
Inclusion: Pediatric or adult patient with a primary or secondary immune deficiency (including immunosuppressive therapy, chemotherapy, HIV infection); mNGS prescription on tissue, CSF, BAL and/or blood to identify the causative pathogen in patient with symptoms or biological signs compatible with an infection as per investigator's judgment (e.g., fever, leukocytosis, increased CRP level); Non opposition of the participant (or parent(s)/ legal guardian(s) of infant participant).
Exclusion: No healthcare insurance.